<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01354704</url>
  </required_header>
  <id_info>
    <org_study_id>PRENOXA_2011</org_study_id>
    <nct_id>NCT01354704</nct_id>
  </id_info>
  <brief_title>Echo-Doppler Assessment of the Occurrence of Asymptomatic DVT in Orthopedic Replacement Surgery Under Enoxaparin</brief_title>
  <acronym>PRENOXA</acronym>
  <official_title>Echo-Doppler Assessment of the Occurrence of Asymptomatic Deep Vein Thrombosis (DVT) in Orthopedic Replacement Surgery Under Enoxaparine (PRENOXA)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Les Laboratoires des Médicaments Stériles</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hospital Charles Nicolle Tunis.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Les Laboratoires des Médicaments Stériles</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objectives of the study are:

      o Objective ultrasound: Determine the presence or absence of subclinical DVT in practicing
      ultrasound-Doppler Day7 and Day35, patients who underwent TKA or THA

      o Clinical objective To evaluate the efficacy and tolerability clinical Enox ® in these
      patients compared with the original drug Lovenox ®.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2011</start_date>
  <completion_date type="Actual">October 2015</completion_date>
  <primary_completion_date type="Actual">July 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Presence or absence of ultrasound findings in favor of asymptomatic DVT</measure>
    <time_frame>Day 7 and 35</time_frame>
    <description>After orthopedic surgery, patients are put under LMWH thromboprophylaxis based but some patients may be carrying an asymptomatic DVT. so we'll try the distal venous thrombosis rate in these patients using Doppler ultrasound.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the efficacy and tolerability clinical Enox ® in these patients.</measure>
    <time_frame>3 months</time_frame>
    <description>Criteria for evaluating the effectiveness of Enox ®:
Onset or without clinical signs of deep vein thrombosis in clinical postoperative
Onset or without clinical signs of pulmonary embolism after surgery</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">153</enrollment>
  <condition>Deep Vein Thrombosis</condition>
  <condition>Venous Thrombosis</condition>
  <condition>Adverse Effect of Anticoagulants</condition>
  <arm_group>
    <arm_group_label>lovenox</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patient under lovenox 4000 IU</description>
  </arm_group>
  <arm_group>
    <arm_group_label>enoxa</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patients under Enoxa 4000 IU</description>
  </arm_group>
  <arm_group>
    <arm_group_label>total knee replacement</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>patients undergoing total knee replacement</description>
  </arm_group>
  <arm_group>
    <arm_group_label>total hip replacement</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>patient undergoing total knee replacement</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Enoxaparin</intervention_name>
    <description>enoxaparin 4000 IU 1 injection/day in subcutaneous.</description>
    <arm_group_label>lovenox</arm_group_label>
    <arm_group_label>enoxa</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  man or woman aged over 18 years, admitted to undergo orthopedic total knee or total
             hip prosthesis requiring the use of enoxaparin 4000 IU for the Prophylaxis.

        Exclusion Criteria:

          -  Patient participating in another study.

          -  hypersensitivity to enoxaparin sodium, heparin unfractionated heparin or other low
             molecular weight.

          -  Patients at risk of major bleeding or uncontrolled including patients with recent
             stroke

          -  Pregnant
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>mondher kooli, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital Charles Nicolle</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ramzi Bouzidi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Charle Nicolle</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mustapha Azaiz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Delta Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Abdelaziz Zarrouk, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Charles Nicollle</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Charle Nicolle</name>
      <address>
        <city>Tunis</city>
        <state>Tunis BAB SOUIKA</state>
        <zip>1006</zip>
        <country>Tunisia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Tunisia</country>
  </location_countries>
  <results_reference>
    <citation>1- Physiopathologie et prévention de la maladie thromboembolique veineuse postopératoire. Charles Marc Samama, Pierre Albaladejo. Sang Thrombose Vaisseaux 2008 ; 20, n°3 :138-43 2- Thromboses veineuses profondes. Dr Jean - Marc Schleich. Département de cardiologie et maladies vasculaires ; CHU de Rennes ; mis à jour le 6 septembre 1998 3- Prévention de la Thrombose veineuse. Dr H. Raybaud - MAJ 2006. Esculape.com : site de médecine générale. 4- Thrombose veineuse profonde. J. - L. Bosson, A. Franco. 1995 SIIM CHU de Grenoble 5- Suivi écho-doppler de thromboses veineuses profondes distales asymptomatique. M.-T BARRELLIER et col. Journal des maladies vasculaires. Masson, 2000, 25, 3 195-200. 6- 83ème Réunion annuelle de la société française de chirurgie orthopédique et traumatologique. Résumé des communications. Revue de chirurgie orthopédique et réparatrice de l'appareil moteur (2008) 94S, S231—S327.</citation>
  </results_reference>
  <verification_date>February 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 14, 2011</study_first_submitted>
  <study_first_submitted_qc>May 16, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 17, 2011</study_first_posted>
  <last_update_submitted>November 2, 2015</last_update_submitted>
  <last_update_submitted_qc>November 2, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 3, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>deep veinous thrombosis</keyword>
  <keyword>enoxaparin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombosis</mesh_term>
    <mesh_term>Venous Thrombosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

